Our Team.

Laura Kleiman, PhD, is the Founder and CEO of Reboot Rx, a nonprofit accelerating access to affordable cancer treatments by repurposing generic drugs. Millions of patients could benefit from these medicines, yet they remain overlooked because no company has a financial incentive to advance off-patent drugs. After losing her mother to cancer and seeing this gap firsthand, Laura launched Reboot Rx to solve it.

Reboot Rx uses AI to identify repurposed generics with the highest likelihood of near-term clinician adoption and large-scale patient impact, and collaborates with national partners such as the Veterans Health Administration and the National Cancer Institute to move these treatments into practice. The organization has earned early support from leading philanthropic funders—including Arnold Ventures, Pershing Square Foundation, and Lyda Hill Philanthropies—and has led policy innovation for generic drug repurposing.

Laura is a Draper Richards Kaplan Foundation Entrepreneur and a Henri Termeer Fellow. Her work has been recognized by 40 Under 40 in Cancer, Extraordinary Women Advancing Healthcare, and the MassNextGen Initiative, and featured in Forbes, The Boston Globe, and Inside Philanthropy. Before founding Reboot Rx, Laura served as a Scientific Research Director at the Dana-Farber Cancer Institute. She earned her PhD in Computational and Systems Biology from MIT and was an American Cancer Society Postdoctoral Fellow at Massachusetts General Hospital and Harvard Medical School.